The standard treatment of Crohn’s disease (Crohn’s disease) is based on the “step-up” strategy. However, results from the PROFILE study indicate that in newly diagnosed Crohn’s disease, early use of a TNF-α inhibitor in combination with an immunomodulator is significantly more effective than stepwise escalation. The recently published results of several years of follow-up show that this also applies to the longer-term outcomes. As interesting as these study results are, in terms of a “best practice” approach, the guideline advises that the respective course of treatment should be assessed individually using surrogate parameters and adjusted accordingly depending on the response.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Secondary prevention after ACS: individually optimized lipid management
Trend towards early combination therapy and new strategies for lowering Lp(a)
- Pediatric Brain Tumors
Psychiatry versus Neuro-Oncology: Diagnostic Pitfalls
- What the latest studies on the entire EF spectrum mean for clinical practice
Heart Failure – The 2026 Evidence Update
- Acute ischemic stroke
Alteplase and Tenecteplase Are on the Same Level
- CKD in People with Type 2 Diabetes: Evidence-Based, Optimized Treatment
SGLT-2 inhibitors and GLP-1 receptor agonists: significant improvement in renal outcomes
- Wearables: screening via smartwatch?
New study on atrial fibrillation in high-risk patients
- Peristomal skin health
Focus on preventive care options
- Planning a Family, Pregnancy, and Breastfeeding